Retatrutide: Both Sides of the Equation at Once

The short version

Retatrutide is an experimental drug, not an approved one. It is a single synthetic peptide that switches on three different hormone receptors at the same time: GLP-1 and GIP, which are incretins — gut hormones released after eating that signal fullness and help control blood sugar — plus the glucagon receptor, which pushes the body to burn stored fuel.

That third receptor is the reason this compound leads the desk. The incretin arms lower how much food is eaten. The glucagon arm raises how much energy is spent. Working both sides of the balance is what separates retatrutide from single- and dual-receptor drugs in the trial numbers so far ^[6].

The published results are large. In a 48-week Phase 2 trial in 338 adults with obesity, the 12 mg weekly arm reached a mean body-weight change of -24.2%, against -2.1% on placebo ^[9]. In a separate study of people with obesity and fatty liver disease, liver fat fell by -82.4% at 24 weeks in the same dose arm ^[8].

The important caution is not a side effect; it is the status. Retatrutide is in Phase 3 trials and has not been approved by any regulator. Every figure on this page comes from a trial publication, measured under clinical supervision. No dose here is a recommendation.

What it is

Retatrutide, also written LY3437943, is a 39-amino-acid synthetic peptide built on a GIP-based backbone. It carries a C20 fatty-diacid acylation, which binds it reversibly to albumin in the blood and slows its clearance; the molecular formula of the free acid is C221H342N46O68. The first-in-human Phase 1b study measured a half-life of approximately six days, which is what supports a once-weekly administration schedule in the trials ^[11].

Its class is the reason it exists: a GIP/GLP-1/glucagon receptor triple agonist, developed as an investigational anti-obesity and anti-diabetic agent. Where earlier compounds engaged one incretin receptor and then two, this molecule engages three receptors, one of which is not an incretin receptor at all.

Regulatory position, stated plainly: retatrutide is investigational, in Phase 3 trials, and not approved by the FDA or any other regulator as of 2026. It is studied only under clinical-trial conditions. There is no approved indication, no approved label, and no consumer or prescription product. Everything reported here is published research, not labelling. Anti-doping status for this receptor class is not specifically prohibited under the current code, but the status of an investigational agent can change and is worth verifying against the current list rather than against this page.

How it works

Three receptors, three jobs, one molecule.

GLP-1 receptor agonism suppresses appetite and improves glucose-dependent insulin secretion. GIP receptor agonism adds a second incretin signal on the same side of the ledger. Glucagon receptor agonism is the departure: controlled activation there increases energy expenditure and mobilises lipid, which is why the compound's weight effect in studies to date is larger than that of dual or single agonists ^[6].

Cryo-electron microscopy has resolved how the molecule sits in each of the three receptors, at resolutions of 2.68, 3.26 and 2.84 angstroms. The structural work also showed the balance is not even: retatrutide is roughly 8.9-fold more potent at the GIP receptor than native GIP, but only 0.3-fold and 0.4-fold as potent as the endogenous hormones at the glucagon and GLP-1 receptors respectively. Extracellular loop 1 adopts a rigid alpha-helix in GLP-1R and GCGR, but stays a flexible loop in GIPR ^[7].

That asymmetry is the design. A glucagon arm at full native potency would be a liability rather than a feature — glucagon raises blood glucose — so the therapeutic idea is a strong incretin signal with a deliberately restrained glucagon signal riding alongside it, enough to lift expenditure without undoing the glycaemic benefit. The Phase 2 glycaemic results are the test of whether that balance holds, and they suggest it does ^[10].

What the research shows

Phase 2, obesity, 48 weeks (2023). In 338 adults with obesity — 51.8% men, BMI at or above 30, or 27 to under 30 with a weight-related comorbidity — once-weekly retatrutide at 12 mg produced a mean body-weight change of -24.2% at 48 weeks against -2.1% on placebo. Gastrointestinal adverse events were dose-related and mostly mild to moderate, and heart rate rose in a dose-dependent way, peaking around week 24 ^[9].

Phase 2, type 2 diabetes, 36 weeks (2023). In 281 adults with type 2 diabetes, the 12 mg arm lowered HbA1c by -2.02% at 24 weeks against -0.01% on placebo, and reduced body weight by 16.94% at 36 weeks against -3.00% on placebo. Mild-to-moderate gastrointestinal adverse events occurred in 35% of participants; there was no severe hypoglycaemia and there were no deaths ^[10].

Phase 2a, metabolic liver disease, 48 weeks (2024). In 98 participants with obesity or overweight and metabolic dysfunction-associated steatotic liver disease, with at least 10% liver fat measured by MRI-PDFF and no type 2 diabetes, relative liver-fat change at 24 weeks ran -42.9%, -57.0%, -81.4% and -82.4% across the 1, 4, 8 and 12 mg arms against +0.3% on placebo. Normal liver fat, below 5%, was reached by 86% of the 12 mg group, and reductions were sustained to 48 weeks, reaching -86.0% at 12 mg ^[8].

Phase 1b, first in human (2022). In 72 adults with type 2 diabetes and HbA1c between 7.0% and 10.5%, retatrutide showed a half-life of approximately six days. The highest-dose group lost 8.96 kg more than placebo over 12 weeks (90% CI -11.16 to -6.75), and daily glucose fell by 2.8 mmol/L at 3 mg. Treatment-emergent adverse events occurred in 63% of participants, mostly gastrointestinal ^[11].

Metabolomics, post-hoc (2026). A post-hoc metabolomic and lipidomic analysis of two Phase 2 randomised trials (282 participants with obesity; 213 with type 2 diabetes) found that higher doses reduced triglycerides — particularly those enriched in short-chain and saturated acyl side chains — and improved biomarkers of insulin resistance including branched-chain amino acids, 2-hydroxybutyrate and urate, in a direction associated with reduced cardiovascular risk. Changes in a fatty-acid-oxidation cluster mediated 23.2% of the weight-reduction response in participants without type 2 diabetes ^[12].

Synthesis (2025). A review of the triple-agonist pharmacology and the Phase 1 and 2 data characterises the roughly 24% weight loss seen at 12 mg over 48 weeks as a step-change relative to prior incretin therapies, and sets it against the gastrointestinal and heart-rate safety profile and the ongoing Phase 3 programme ^[6].

Reported effects, cautions & safety

What follows in this first block is anecdotal, not clinical evidence: unverified self-reports collected from research-use communities, with no clinical oversight, no confirmed material and no verified quantities behind them. No amounts are attached to any of it, and none of it should be read as an outcome anyone can expect.

Frequently reported as benefits. Near-total suppression of appetite is the dominant theme — community members describe intrusive food thoughts going quiet, and characterise it as disinterest in eating rather than active fullness. Weight reduction that feels faster than experiences with other compounds in this class is reported almost as often. Commonly reported: a sensation of running warm — flushing, sweating more easily, a low-grade heat unlike exertion — which community discussion attributes to the glucagon arm and its thermogenic effect. Occasionally reported: a lift in mood and a lighter relationship with food.

Frequently reported as side effects. Nausea, concentrated in the early weeks and after stepping up, described as peaking some hours after administration and easing with time. Commonly reported: sulfur-smelling burps attributed to slowed gastric motility; fatigue and low energy in the first weeks, often linked by reporters to sharply reduced intake; constipation; and awareness of a faster resting pulse, sometimes observed on wearables. Occasionally reported: localised itching or redness at an injection site resolving within a day or two, disturbed sleep in the early weeks, and — among people who track body composition — a sense that rapid loss feels soft.

The documented cautions are a different class of statement. They come from trials and regulators, not from forums.

• Unapproved and unverified outside a trial. Retatrutide has not been approved by any regulator. Material obtained outside a clinical trial has no verified identity, purity or sterility; analyses of comparable grey-market peptides have found truncated sequences, racemised amino acids and entirely different compounds, and without sterility and endotoxin testing an injectable carries contamination risk up to sepsis. The FDA has issued warning letters to retatrutide vendors citing Federal Food, Drug, and Cosmetic Act violations ^[6].
• Dose-dependent gastrointestinal events. Nausea, vomiting, diarrhoea and constipation were the leading reason for discontinuation in Phase 2. Nausea affected up to 45% of participants in the highest-dose arm and drove the 18% discontinuation rate at that level; the mechanism is GLP-1-mediated slowing of gastric emptying. Trials escalate deliberately under supervision, which unmonitored use does not ^[9].
• Heart rate. Mean increases of roughly 5 to 7 beats per minute were recorded at the highest doses, peaking around week 24, driven by glucagon-receptor chronotropy. A dedicated cardiovascular outcomes trial is ongoing and has not reported ^[9].
• Interaction with insulin and sulfonylureas. Incretin-driven insulin secretion on top of already-elevated insulin can drive glucose below safe thresholds. Trial participants on background insulin required de-escalation of that insulin during the study, under monitoring ^[10][11].
• Lean mass. Body-composition analysis in this programme records reductions in lean mass alongside fat mass during rapid weight loss, a finding that is being examined across the class rather than being unique to this compound.
• The long-term record does not exist yet. The Phase 3 programme and dedicated cardiovascular and kidney outcome trials are ongoing. Durability of weight loss after stopping, long-term cardiovascular and renal safety, and effects on cardiac remodelling are all uncharacterised.

Where it fits in energy balance

Retatrutide is the only compound on this desk that is documented to act on both sides of the balance at once, and that is the entire reason it leads the theme.

On the intake side it does what the incretin class does: GLP-1 and GIP receptor agonism reduce food intake and improve glucose-dependent insulin secretion. On the expenditure side, controlled glucagon-receptor activation raises energy expenditure and mobilises lipid ^[6]. The metabolomic analysis puts a number on how much of the result travels by the second route — changes in a fatty-acid-oxidation cluster mediated 23.2% of the weight-reduction response in participants without type 2 diabetes ^[12] — which is as close as this literature gets to separating burning from eating less.

The liver-fat result belongs to the same story rather than to a separate one. Fat stored in the liver is the storage term of the equation made visible on a scan, and reductions of -82.4% at 24 weeks, sustained to -86.0% at 48 weeks in the highest-dose arm, describe a compound shifting stored substrate rather than only closing an intake gap ^[8].

Set against semaglutide, whose weight effect is described as central and appetite-driven without a lowering of energy expenditure, and against MOTS-c, which acts inside the cell with no completed human efficacy trial behind it, retatrutide occupies the middle of the frame: the widest mechanism and, for now, the thinnest long-term record. The side-by-side page lines the three up on those terms.